DROID: dose-ranging approach to optimizing dose in oncology drug development

DOI10.1111/BIOM.13840zbMATH Open1543.62598MaRDI QIDQ6589229FDOQ6589229

Authors: Beibei Guo, Ying Yuan 

Publication date: 19 August 2024

Published in: Biometrics (Search for Journal in Brave)

zbMATH Keywords

maximum tolerated dosedose-response relationshiptargeted drugsoptimal doserisk-benefit assessment

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites Work

• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs
• Title not available (Why is that?)
• Bayesian inference on order-constrained parameters in generalized linear models
• Combining Multiple Comparisons and Modeling Techniques in Dose‐Response Studies
• Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
• Bayesian designs for phase I--II clinical trials
• A Bayesian phase I/II trial design for immunotherapy
• Bayesian optimal interval designs for phase I clinical trials
• A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies
• gBOIN: a unified model-assisted phase I trial design accounting for toxicity grades, and binary or continuous end points

Cited In (2)

• Design and sample size determination for multiple-dose randomized phase II trials for dose optimization
• A seamless phase II/III design with dose optimization for oncology drug development

This page was built for publication: DROID: dose-ranging approach to optimizing dose in oncology drug development

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6589229)